Clinical Factors Associated with Stroke Recurrence in Atrial Fibrillation Patients

Authors

DOI:

https://doi.org/10.30872/

Keywords:

Warfarin, atrial fibrillation, recurrent stroke

Abstract

Recurrent stroke in patients with atrial fibrillation (AF) remains a clinical problem despite warfarin therapy. This study aimed to identify clinical factors associated with recurrent stroke in AF patients receiving warfarin. A retrospective cohort study was conducted among 50 patients with ischemic stroke and AF who received warfarin for at least one year at Dr. Sardjito General Hospital, Yogyakarta, and Dr. Moewardi General Hospital, Surakarta, during 2015–2019. Bivariate and multivariate logistic regression analyses were performed to assess the association between clinical factors and recurrent stroke. Eleven patients (22%) experienced recurrent stroke. Bivariate analysis showed that warfarin dose switching, dose variation, and body mass index were associated with recurrent stroke. However, conventional multivariate logistic regression and Firth’s penalized logistic regression did not confirm these variables as significant independent predictors. The wide confidence intervals, which included 1, reflected the limited sample size and number of events. Mean INR (p=0.06) and INR monitoring frequency (p=0.27) were also not significantly associated with recurrent stroke. This study concludes that no clinical factor was identified as a significant independent predictor of recurrent stroke. The findings are exploratory and support comprehensive therapeutic management, including maintaining warfarin dose stability and considering patient characteristics such as body mass index

Author Biographies

  • Lailla Affianti Fauzi, Yogyakarta State University

    Department of Indonesian Traditional Medicine, Faculty of Vocational Studies, Yogyakarta State University, Yogyakarta, Indonesia

  • Erna Kristin, Universitas Gadjah Mada

    Department of Pharmacology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

  • Rizaldy Taslim Pinzon, Duta Wacana Christian University

    Faculty of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia

References

[1] V. L. Feigin et al., “World Stroke Organization (WSO): Global Stroke Fact Sheet 2022,” Int. J. Stroke, vol. 17, no. 1, pp. 18–29, 2022, doi: 10.1177/17474930211065917.

[2] World Stroke Organization, “Global Stroke Fact Sheet 2022,” 2022. [Online]. Available: https://www.world-stroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf

[3] Y. Zhao, C. Zou, C. Wang, Y. Zhang, and S. Wang, “Long-term outcomes after stroke in elderly patients with atrial fibrillation: A hospital-based follow-up study in China,” Front. Aging Neurosci., vol. 8, Art. no. 56, 2016.

[4] K. Sánchez-Acosta, L. Galeano, D. Villarreal, A. Montoya, and H. Bayona, “Recurrent stroke due to atrial fibrillation: Perspectives about an unsolved problem,” Rev. Colomb. Cardiol., vol. 30, no. 3, pp. 185–192, 2023.

[5] H. Kamel et al., “Detection of atrial fibrillation after stroke and the risk of recurrent stroke,” J. Stroke Cerebrovasc. Dis., vol. 21, no. 8, pp. 726–731, 2012, doi: 10.1016/j.jstrokecerebrovasdis.2011.03.008.

[6] T. A. Nathan, R. Wibowo, R. Sasongkojati, B. Hartoko, and D. T. Butarbutar, “Prevalence of atrial fibrillation in ischemic stroke and associated risk factors: A hospital-based study in Indonesia,” Brain Circ., vol. 10, no. 4, pp. 316–323, 2024, doi: 10.4103/bc.bc_36_24.

[7] C. T. January et al., “2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society,” J. Am. Coll. Cardiol., vol. 74, no. 1, pp. 104–132, 2019, doi: 10.1016/j.jacc.2019.01.011.

[8] R. Galea, D. Seiffge, and L. Räber, “Atrial fibrillation and ischemic stroke despite oral anticoagulation,” J. Clin. Med., vol. 12, no. 18, 2023, doi: 10.3390/jcm12185784.

[9] M. Paciaroni et al., “Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention: The RENo study,” Stroke, vol. 50, no. 8, pp. 2168–2174, 2019, doi: 10.1161/STROKEAHA.119.025350.

[10] J. Petch et al., “Optimizing warfarin dosing for patients with atrial fibrillation using machine learning,” Sci. Rep., vol. 14, no. 1, pp. 1–13, 2024, doi: 10.1038/s41598-024-55110-9.

[11] L. A. Fauzi, E. Kristin, R. T. Pinzon, B. M. W. Kushartanti, and N. I. Arovah, “Effects of switching dose, dose variation, and warfarin interaction on the incidence of stroke recurrence in stroke patients with atrial fibrillation,” Borneo J. Pharm., vol. 7, no. 3, pp. 315–323, 2024, doi: 10.33084/bjop.v7i3.6603.

[12] W. W. Nelson et al., “International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation,” Am. J. Cardiovasc. Drugs, vol. 15, no. 3, pp. 205–211, 2015, doi: 10.1007/s40256-015-0120-9.

[13] W. P. Nilamsari, M. Yusuf, D. A. Pertiwi, A. Dery, S. Budi, and B. Zulkarnaen, “Study of co-prescription of drugs potentially interacting with warfarin in Indonesian ambulatory patients,” Res. J. Pharm. Technol., vol. 13, no. 8, pp. 3833–3836, 2020.

[14] N. A. Putriana, I. R. Latarissa, T. Rusdiana, T. Rostinawati, and M. R. Akbar, “Pharmacodynamic modeling of warfarin dosing algorithm for cardiovascular patients in Indonesia: A tailored method to anticoagulation therapy,” Drug Des. Devel. Ther., vol. 19, pp. 671–681, 2025, doi: 10.2147/DDDT.S497738.

[15] M. F. Hindsholm et al., “Recurrent ischemic stroke in patients with atrial fibrillation while receiving oral anticoagulants,” JAMA Neurol., vol. 81, no. 8, pp. 805–813, 2024, doi: 10.1001/jamaneurol.2024.1892.

[16] A. Alshammari, A. Altuwayjiri, Z. Alshaharani, R. Bustami, and H. S. Almodaimegh, “Warfarin dosing requirement according to body mass index,” Cureus, vol. 12, no. 10, 2020.

[17] V. Sorodoc et al., “Anticoagulation approach in morbid obesity: A comprehensive review on venous thromboembolism management,” Front. Pharmacol., vol. 15, Art. no. 1457280, pp. 1–22, 2024, doi: 10.3389/fphar.2024.1457280.

[18] S. Yaghi et al., “Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation,” J. Stroke Cerebrovasc. Dis., vol. 29, no. 7, Art. no. 104888, 2020, doi: 10.1016/j.jstrokecerebrovasdis.2020.104888.

Downloads

Published

2026-09-30

Issue

Vol. 7 No. 3 (2026): J. Sains Kes.

Section

Articles

License

Copyright (c) 2026 Lailla Affianti Fauzi, Erna Kristin, and Rizaldy Taslim Pinzon

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
L. A. Fauzi, E. Kristin, and R. T. Pinzon, “Clinical Factors Associated with Stroke Recurrence in Atrial Fibrillation Patients”, J. Sains. Kes, vol. 7, no. 3, pp. 72–81, Sep. 2026, doi: 10.30872/.

Similar Articles

1-10 of 17

You may also start an advanced similarity search for this article.